Mobile

An eight-week, double-blind, group sequential design, placebo controlled trial to evaluate the safety and efficacy of the co-administration of sertraline and elzasonan (CP-448,187) in outpatients with...

Mise à jour : Il y a 5 ans
Référence : EUCTR2005-004780-34

An eight-week, double-blind, group sequential design, placebo controlled trial to evaluate the safety and efficacy of the co-administration of sertraline and elzasonan (CP-448,187) in outpatients with major depressive disorder

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare the efficacy of the administration of sertraline and elzasonan combination (SEC) to sertraline monotherapy in the acute treatment of subjects with MDD as measured by Montgomery-Asberg Depression Rating Scale (MADRS) remission rates at Week 8.

Critère d'inclusion

  • -Major Depressive Disorder (MDD)

Liens